Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exablate Blood-Brain Barrier Disruption with mAb Therapy in MCI or Mild AD
NCT05469009Phase 1Active, not recruiting
- Sponsor
- WVU Rockefeller Neuroscience Institute
- Start
- Jul 2022
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), sponsored by WVU Rockefeller Neuroscience Institute. Primary endpoints: Treatment intervention related adverse events at 5 years and Treatment intervention related serious adverse events at 5 years. Started Jul 2022; status: active, not recruiting.
02
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05469009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469009.